In this report, two cases of uterine smooth muscle cell tumors, one of uncertain malignant potential and one clearly malignant, are described in women treated for prolonged periods with luteinizing hormone-releasing hormone (LH-RH) analogues. Due to lengthy monitoring of LH-RH therapy, surgical intervention and histologic classification of these tumors was late in the course of disease, resulting in a delay in definite treatment. The risk to these women is discussed. The effects of LH-RH analogue therapy on fibroids is reviewed. Suggestions are put forward for monitoring LH-RH analogue therapy.

, ,,
European Journal of Obstetrics & Gynecology and Reproductive Biology
Department of Pathology

Wauters, C. C. A. P., ter Harmsel, B., Hermans, M. P. M., & Smedts, F. (1995). Unexpected borderline malignant and malignant smooth muscle cell tumors of the uterine corpus in women treated with LH-RH analogues. European Journal of Obstetrics & Gynecology and Reproductive Biology, 62(2), 257–259. doi:10.1016/0301-2115(95)02192-A